Key result
Orofacial pain medications including TCAs and anticonvulsants may exacerbate arrhythmias and SCD in Brugada syndrome.
Why the study?
Long-term orofacial pain regimens can alter cardiac ion channels and autonomic tone, risking ventricular arrhythmias in Brugada syndrome, yet most dental guidance addresses only short-term local anesthetics.
Do specific orofacial pain medications trigger malignant ventricular arrhythmias or unmask type 1 Brugada patterns in patients with Brugada syndrome?
Do specific orofacial pain medications trigger malignant ventricular arrhythmias or unmask type 1 Brugada patterns in patients with Brugada syndrome?
Orofacial pain specialists must screen for Brugada syndrome and avoid or closely monitor the use of specific sodium-channel blocking analgesics, TCAs, and anticonvulsants to prevent fatal arrhythmias.
Answers are grounded in this paper and cite their sources.
Supports screening for Brugada syndrome before TCA or anticonvulsant use in orofacial pain; hypothesis-generating and requires prospective confirmation.
Orofacial pain, diagnosed and treated in a subfield of dentistry, highly relies on long-term psychotropic, neuromodulating, and analgesic regimens that have the potential to alter cardiac ion channels and autonomic tone. In patients with inherited arrhythmia syndromes such as Brugada syndrome (BrS), these drugs may unmask a type 1 Brugada electrocardiographic pattern or trigger malignant ventricular arrhythmias and sudden cardiac death, yet most dental guidance addresses only short-term use of local anesthetics. In this narrative review, we synthesize evidence on the arrhythmogenic potential of medications used for orofacial pain—non-steroidal anti-inflammatory drugs, tricyclic antidepressants, anticonvulsants, and primary headache therapies. Finally, we propose a pragmatic risk-stratified approach for orofacial pain specialists. Incorporating channelopathy-specific precautions into orofacial pain pharmacotherapy may reduce drug-induced ventricular arrhythmias and sudden cardiac death while preserving effective long-term pain control.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied Brugada syndrome. Orofacial pain medications vs. Control or alternative medications was evaluated on Risk of drug-induced arrhythmias and sudden cardiac death in patients with Brugada syndrome. Certain medications for orofacial pain, such as tricyclic antidepressants and anticonvulsants, may exacerbate arrhythmias in patients with Brugada syndrome, posing risks of sudden cardiac death.
Synapse has enriched 10 related papers. Consider them for comparative context: